Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Kohjiro UekiYukio TanizawaJiro NakamuraYuichiro YamadaNobuya InagakiHirotaka WatadaIichiro ShimomuraRimei NishimuraHideaki MiyoshiAtsuko AbikoHideki KatagiriMichio HayashiAkira ShimadaKeiko NaruseShimpei FujimotoMasazumi FujiwaraKenichi ShikataYosuke OkadaEiichi ArakiTsutomu YamazakiTakashi Kadowakinull nullPublished in: BMJ open diabetes research & care (2021)
Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting.
Keyphrases